華仁藥業(300110.SZ):曲江華仁擬以8億元收購恆聚星醫藥100%股權 並間接控股恆星製藥
格隆匯7月23日丨華仁藥業(300110.SZ)公佈,2021年7月23日,公司全資子公司西安曲江華仁藥業有限公司(“曲江華仁”)與本次收購交易對方玉林市健鑫商業合夥企業(有限合夥)、宜春聚特星商貿中心(有限合夥)、宜春景物星科技合夥企業(有限合夥)、宜春聚胺星電子商務合夥企業(有限合夥)、宜春聚代星數字科技中心(有限合夥)簽署了《關於西安恆聚星醫藥有限公司暨安徽恆星製藥有限公司100%股權的股權收購協議》,曲江華仁以自有資金8億元收購交易對方持有的西安恆聚星醫藥有限公司(“恆聚星醫藥”、“標的公司”)100%股權,並間接持有恆星製藥100%股權。
交易完成後,公司將通過全資子公司曲江華仁持有恆聚星醫藥100%股權,並間接持有恆星製藥100%股權,恆星製藥將成為公司三級全資子公司,納入公司合併報表範圍。
本次收購,一方面,能夠進一步豐富公司藥品品種,增加公司的藥品劑型,積極應對國家集採等行業變革。公司通過本次收購能夠快速取得過評品種、集採品種和在研品種,進一步豐富公司的藥品品種和研發管線,推動公司在研發平台建設上創新升級和快速發展,以賦能公司實現快速穩定發展。
收購完成後,公司將積極開展恆星製藥呼吸科、精麻類等品種與公司現有品種的渠道融合、生產、團隊融合,實現資源共享,充分發揮協同效應,實現現有品種的快速放量。
另一方面,能夠進一步提升公司盈利能力和可持續經營能力,為公司帶來新的業績增長點。本次收購交易對方承諾,在2021-2023年的業績對賭期間,恆星製藥將分別實現6000萬元、8000萬元、10000萬元的扣非淨利潤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.